VANCOUVER, BC, CANADA (February 12th, 2020) – Codebase Ventures Inc. ("Codebase" or the "Company") (CSE: CODE - FSE: C5B – OTCQB: BKLLF), an investment company, on behalf of its subsidiary, Titan Shrooms and Psychedelics, is pleased to provide an overview of the rapidly changing environment for natural psychedelics in the USA.

There is a growing body of scientific research, as reported by 60 Minutes,1 indicating that psilocybin can be used to effectively treat mental illnesses such as anxiety, depression and PTSD – and more so where these conditions are entrenched and current drugs are not proving effective. A study reported in the journal Nature2, showed that 47% of patients with treatment resistant depression who received psilocybin were showing positive outcomes 5 weeks post treatment.

In addition, the FDA has granted “breakthrough therapy” status to both the Usona Institute and Compass Pathways, allowing clinical trials to advance – a measure the organization deploys where evidence indicates there could be substantial improvement over currently available treatments.3

As a result of this movement, stigmas are being reduced and cities and regions are moving quickly to decriminalize natural psychedelics such as psilocybin including:

Pending measures underway in:

“Although in early stages, this rapidly developing field is being validated by the medical establishment, legislative bodies and most importantly patients who are seeing benefits,” said Mr. George Tsafalas. “Titan Shrooms and Psychedelics is working to add to its portfolio so that Code shareholders can benefit from the continued acceptance and growth in this sector.”